Washington Trust Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Washington Trust Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30	Closed	-$5.96K	–	594
2025 Q3	$5.96K	Sell	30 -22	-42%	-$4.1K	﹤0.01%	596
2025 Q2	$8.97K	Hold	52	–	–	﹤0.01%	493
2025 Q1	$8.11K	Buy	52 +14	+37%	+$2K	﹤0.01%	495
2024 Q4	$5.23K	Hold	38	–	–	﹤0.01%	562
2024 Q3	$5.67K	Hold	38	–	–	﹤0.01%	555
2024 Q2	$5.18K	Hold	38	–	–	﹤0.01%	549
2024 Q1	$5.75K	Hold	38	–	–	﹤0.01%	551
2023 Q4	$4.79K	Hold	38	–	–	﹤0.01%	576
2023 Q3	$3.56K	Hold	38	–	–	﹤0.01%	590
2023 Q2	$3.39K	Hold	38	–	–	﹤0.01%	586
2023 Q1	$4.08K	Hold	38	–	–	﹤0.01%	642
2022 Q4	$4.64K	Hold	38	–	–	﹤0.01%	619
2022 Q3	$4K	Hold	38	–	–	﹤0.01%	739
2022 Q2	$4K	Hold	38	–	–	﹤0.01%	772
2022 Q1	$4K	Hold	38	–	–	﹤0.01%	840
2021 Q4	$5K	Buy	+38	New	+$5.65K	﹤0.01%	839

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Washington Trust Advisors's ASND Position: Q4 2025 in Review

Washington Trust Advisors sold out of Ascendis Pharma A/S (ASND) in Q4 2025, closing a stake of 30 shares — an estimated $5.96K sold.

Washington Trust Advisors first reported a position in ASND in Q4 2021 and held it in 16 quarters. The position peaked at $8.97K in Q2 2025. 302 funds tracked by Wall St. Rank hold ASND as of Q4 2025.

Washington Trust Advisors reported no remaining Ascendis Pharma A/S position as of Q4 2025 after selling out during the quarter.
Washington Trust Advisors sold 30 Ascendis Pharma A/S shares in Q4 2025, an estimated $5.96K.
Washington Trust Advisors first reported a position in Ascendis Pharma A/S in Q4 2021 and held it in 16 quarters.
Washington Trust Advisors's Ascendis Pharma A/S position peaked at $8.97K in Q2 2025.
302 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2025.

Based on Washington Trust Advisors's 13F filing for Q4 2025, filed 3 Feb 2026.